H W Herr


Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA


  1. Herr H, Donat M. Reduced Recurrence of Low-grade Papillary Bladder Tumors Associated With Asymptomatic Bacteriuria. Urology. 2019;124:179-182 pubmed publisher
    ..Bladder-resident bacteria may reduce bladder tumor recurrences through local immune mechanisms. ..
  2. request reprint
    Herr H, Bochner B, Sharp D, Dalbagni G, Reuter V. Urachal carcinoma: contemporary surgical outcomes. J Urol. 2007;178:74-8; discussion 78 pubmed
    ..Wide resection of the tumor mass and entire urachus resulting in negative soft tissue and bladder margins cures the majority of nonmetastatic urachal cancers. ..
  3. request reprint
    Herr H, Donat S, Reuter V. Management of low grade papillary bladder tumors. J Urol. 2007;178:1201-5; discussion 1205 pubmed
    ..Surveillance cystoscopy at 6-month intervals coupled with outpatient fulguration controls recurrent tumors and reduces the therapeutic burden for patients diagnosed with low grade papillary bladder tumors. ..
  4. Herr H. Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results. BJU Int. 2010;105:314-6 pubmed publisher
    ..NBIC outperformed urine cytology in detecting residual tumour after BCG therapy. NBIC appears to better identify patients who have suspected residual tumour on follow-up WLC at 3 months after BCG therapy. ..
  5. Herr H, Dalbagni G, Donat S. Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol. 2011;60:32-6 pubmed publisher
    ..Our results with BCG treatment without maintenance of patients with high-risk non-muscle-invasive bladder cancer compare favorably with trials in which comparable patients received maintenance BCG. ..
  6. Herr H. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187:435-7 pubmed publisher
    ..Such strategy facilitates the timely administration of bacillus Calmette-Guérin therapy and avoids the overuse of antibiotics. ..
  7. Al Hussein Al Awamlh B, Lee R, Chughtai B, Donat S, Sandhu J, Herr H. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology. 2015;85:381-6 pubmed publisher
    ..Adherence to an office-based treatment plan can lead to significant cost savings with a decreased therapeutic burden over the lifetime of a patient with NMIBC. ..
  8. Herr H, Milan T, Dalbagni G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol. 2015;33:108.e1-4 pubmed publisher
    ..3 (20%) of the 15 BCG-relapsing patients. BCG-refractory and BCG-relapsing categories differentiate BCG-failed patients into high-and lower-risk prognostic groups that may be useful in guiding treatment strategies. ..
  9. request reprint
    Herr H, McAninch J. Urethral injuries in the Civil War. J Urol. 2005;173:1090-3 pubmed
    ..Only 19 patients (23%) recovered fully. Civil War urethral injuries had devastating long-term consequences. ..

More Information


  1. Herr H. 'I will not cut . . . ': the oath that defined urology. BJU Int. 2008;102:769-71 pubmed publisher
    ..The Hippocratic Oath actually defined, identified and legitimized urology as the first medical speciality. ..
  2. Herr H. Role of re-resection in non-muscle-invasive bladder cancer. ScientificWorldJournal. 2011;11:283-8 pubmed publisher
    ..Our conclusions show thatrestaging TUR improves the outcomes of high-risk,non-muscle-invasive bladder neoplasms. ..